Ticker brief
BIIB BIOGEN INC
Consumer, Non-cyclical · Biotechnology
last close
$250.69
1 day
-1.2%
14 days
+11.1%
mkt cap
$31.9B
signals 14d
30
authors 14d
24
crowd 14d
+2.0σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 46% rich · 94 pctile own 1y | IV/HV 1.49× |
| Skew — 25Δ RR 30d | -0.037 23 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +0.99 normal | 5-session Δ +0.38 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2025-11-04 (z=2.1) |
| Next earnings | 2026-10-28 (proj) | in 2d |
Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-15 · now +0.35 (−1 bearish … +1 bullish)
Who spoke24
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @CHItrader | B | -0.22 | 2 | +0.40 |
| @MktBrain_US | C | +0.35 | 2 | +0.38 |
| @newsinvesting | C | · | 2 | +0.38 |
| @MinervaCap | C | -1.56 | 2 | +0.42 |
| @cnfinancewatch | B | -1.23 | 2 | +0.48 |
| @ivanhoff | C | -1.07 | 2 | +0.35 |
| @VistaPResearch | C | · | 1 | +0.35 |
| @PeloSwing | C | +1.05 | 1 | +0.35 |
| @BeatTheInsider | C | · | 1 | -0.20 |
| @FL0WG0D | C | · | 1 | +0.35 |
| @Tradinguru55 | C | · | 1 | +0.40 |
| @CNBC | C | +0.31 | 1 | +0.40 |
| @t3live | C | -0.10 | 1 | +0.31 |
| @zerohedge | C | -2.79 | 1 | -0.24 |
| @SpartanTrading | C | +1.30 | 1 | +0.00 |
| @beikoku05 | C | -1.13 | 1 | +0.40 |
| @porquettfin | C | -1.14 | 1 | +0.40 |
| @semodough | C | -1.06 | 1 | +0.40 |
| @schaeffers | C | +1.18 | 1 | +0.40 |
| @OptionsFlowBoss | C | · | 1 | +0.25 |
| @KeithTradeSmith | C | +1.08 | 1 | +0.40 |
| @alexkoh | B | -1.37 | 1 | +0.40 |
| @AryaFintech | C | -1.41 | 1 | +0.20 |
| @financespotnews | C | +0.40 | 1 | +0.40 |
Recent signals30of 30 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @ivanhoff | +0.35 | Relative-strength leadership is rotating toward defensive healthcare and staples names. | +6.5% | tweet ↗ |
| 2026-10-15 | @cnfinancewatch | +0.35 | Quant screen ranks US stocks by base location, profit positioning and recent price action. | +6.5% | tweet ↗ |
| 2026-10-14 | @ivanhoff | +0.35 | Several biotechs are reaching 52-week relative-strength highs versus SPY. | +7.7% | tweet ↗ |
| 2026-10-14 | @cnfinancewatch | +0.60 | Reports multiple analyst PT actions, led by JPMorgan's BIIB upgrade and PT increase. | +7.7% | tweet ↗ |
| 2026-10-13 | @financespotnews | +0.40 | JPMorgan upgrades Biogen to Overweight from Neutral. | +9.5% | tweet ↗ |
| 2026-10-12 | @MinervaCap | +0.45 | Detailed market-close framework covering rotation, AI catalysts, upgrades, and memory weakness. | +9.3% | tweet ↗ |
| 2026-10-12 | @AryaFintech | +0.20 | Lists five S&P 500 stocks hitting 52-week highs. | +9.3% | tweet ↗ |
| 2026-10-12 | @alexkoh | +0.40 | JPMorgan upgraded Biogen to Overweight. | +9.3% | tweet ↗ |
| 2026-10-12 | @KeithTradeSmith | +0.40 | Describes rotation toward profitable cybersecurity and healthcare leaders making new highs. | +9.3% | tweet ↗ |
| 2026-10-12 | @OptionsFlowBoss | +0.25 | Reports unusual bullish options-volume multiples; ticker output is capped at six. | +9.3% | tweet ↗ |
| 2026-10-12 | @schaeffers | +0.40 | Flags analyst upgrades for CRM, BIIB and FSLR, including a $300 BIIB price target. | +9.3% | tweet ↗ |
| 2026-10-12 | @semodough | +0.40 | JPMorgan upgrades Biogen to Overweight from Neutral with a $300 target. | +9.3% | tweet ↗ |
| 2026-10-12 | @newsinvesting | +0.35 | Biogen reaches a new 52-week high after a 56% one-year rally amid improving analyst sentiment. | +9.3% | tweet ↗ |
| 2026-10-12 | @MktBrain_US | +0.35 | Biogen shares rose as much as 5.6%, their largest intraday gain since July 29. | +9.3% | tweet ↗ |
| 2026-10-12 | @porquettfin | +0.40 | BofA, Truist and JPMorgan issued favorable upgrades on Salesforce, First Solar and Biogen. | +9.3% | tweet ↗ |
| 2026-10-12 | @beikoku05 | +0.40 | Premarket roundup reports multiple analyst upgrades plus IREN contract news; tickers capped at six. | +9.3% | tweet ↗ |
| 2026-10-12 | @MinervaCap | +0.40 | Morning framework synthesizes macro, AI infrastructure, software upgrades, and memory competition. | +9.3% | tweet ↗ |
| 2026-10-12 | @SpartanTrading | +0.00 | Premarket watch list without directional entry intent. | +9.3% | tweet ↗ |
| 2026-10-12 | @newsinvesting | +0.40 | JPMorgan upgrades Biogen to Overweight with a $300 target ahead of potential 2027 catalysts. | +9.3% | tweet ↗ |
| 2026-10-12 | @CHItrader | +0.40 | Analyst upgrade roundup lists new ratings and targets; extraction is capped at six tickers. | +9.3% | tweet ↗ |
| 2026-10-12 | @MktBrain_US | +0.40 | Premarket roundup reports analyst actions, trial success and acquisition talks. | +9.3% | tweet ↗ |
| 2026-10-12 | @zerohedge | -0.24 | Premarket roundup reports analyst actions and company catalysts across six directly affected stocks | +9.3% | tweet ↗ |
| 2026-10-12 | @t3live | +0.31 | Provides premarket futures, commodity, crypto and leading SPX-gainer performance data. | +9.3% | tweet ↗ |
| 2026-10-12 | @CNBC | +0.40 | JPMorgan expects significant Biogen gains from upcoming trial-data releases. | +9.3% | tweet ↗ |
| 2026-10-12 | @Tradinguru55 | +0.40 | JPMorgan upgraded BIIB to Overweight from Neutral and set a $300 target. | +9.3% | tweet ↗ |
| 2026-10-09 | @FL0WG0D | +0.35 | Reports $1.3 million of premium flowing into BIIB calls. | +11.1% | tweet ↗ |
| 2026-10-09 | @CHItrader | +0.40 | Reports multiple new bullish sell-side coverage initiations; output is capped at six tickers. | +11.1% | tweet ↗ |
| 2026-10-08 | @BeatTheInsider | -0.20 | New political disclosure lists sales in six named companies. | +14.8% | tweet ↗ |
| 2026-10-07 | @PeloSwing | +0.35 | Reports more than $144,000 in BIIB January $260 calls. | +12.8% | tweet ↗ |
| 2026-10-05 | @VistaPResearch | +0.35 | Frames the Nobel Prize in Medicine as illuminating a new bull market for brain-science companies. | +12.1% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.